Drone envisioned to deliver defibrillator implant; Intelomed raises $4M for cardiovascular monitoring tools;

@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev

@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce

@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce

> New U.K. research hasn't turned up any evidence that all-metal hip replacements increase the risk of cancer. Story

> Israel's Keystone Heart gained a CE marking for its new TriGuard device, which is designed to help minimize the risk of brain damage during a transcatheter aortic valve replacement procedure. Item

> ICU Medical ($ICUI) won the FDA's 510(k) clearance for its ChemoLock needle-free closed system transfer device, which is designed, in part, to keep clinicians and patients safe from exposure to hazardous drugs. Item

> German researchers are developing a drone that would deliver a defibrillator to a patient suffering a heart attack. Story

> Florida officials are pitching their state as a place that is becoming a hotspot for medical device and other life sciences companies. Story

> Intelomed brought in a $4M Series A-1 round to help back clinical tests and sales efforts for its noninvasive devices and software designed to monitor cardiovascular stability. Item

Biotech News

@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech

@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce

@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride

@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce

> DRI Capital gains $1.45B in fresh firepower for drug royalty deals. Report

> Biogen fronts $100M to add Isis R&D pact on neurological diseases. Story

> Crowded field of PhIII COPD contenders will compete for blockbuster market. Article

Pharma News

@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma

@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce

@CarlyHFierce: GlaxoSmithKline selling two drinks brands to Japan's Suntory. Release | Follow @CarlyHFierce

> Boehringer targets sales reps in new round of French job cuts. Report

> Bayer's Xarelto faces stepped-up reports of side effects, deaths. Story

CRO News

> Novella shuffles execs as Quintiles deal pends. Item

> AMRI chief stepping down at year's end. News

> Patheon posts Banner quarter on 30% sales surge. Article

> Covance teams with Indiana U. for early trials. Story

> Capsugel snaps up Bend with eye on oral formulations. More

Biotech IT News

> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report

> Texas biotech software outfit trumpets open source tools. Item

> Genentech backs development of video game for kids with cancer. More

> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story

> Accelrys scoops up Bay Area software firm for $15.3M. Article